All News

Shipping containers may be carrying mold into cleanrooms.

Interactive national map shows vaccine rates and epidemic data.

Will there be enough yellow fever vaccine if Brazil’s epidemic spreads?

What’s been going on in the biopharmaceutical industry?

The Nevada law to fight high diabetes drug prices has stumbled.

Drug makers are starting plans to help patients pay for diabetes drugs.

NCPA sends letter to Senate on prescription issues in health-care reform.

A Letter to the Editor about our recent article on opioid addiction.

Gottlieb and Trump want faster drug approvals to help more patients, but studies show faster approvals might cause harm.

Study finds that all NSAIDs are associated with an increased risk of acute myocardial infarction.

How Inside Rx could save patients money.

One pharmacist decided to find out how long an EpiPen stays useable.

See how your state stacks up-Is it time for a move?

Pharmacists can access drug information from multiple companies with one click.

Managing post-op pain is a team effort-and who better to lead the team than a medication expert?

What a large national chain is doing to combat opioid abuse (and what other pharmacies can learn from it).

New QuintilesIMS data shows that the growth in drug spending is leveling off.

A new campaign takes aim at drug prices, but is it the right approach?

NCPA’s recommendations for improving the “increasingly complicated Part D marketplace.”

What you need to know about the the 10 newest FDA drug approvals.

Marsh Supermarkets announced that it is selling its pharmacy operations.

The 113th Annual Meeting will feature CPE, discussions, and more.

Did major chain pharmacies and distributors contribute to the opioid epidemic in Oklahoma?

The second Remicade biosimilar is only the fifth biosimilar approved in the United States.

Anthem is parting ways with Express Scripts.

NACDS’s Gourlay embraces leading the industry proactively through changing health-care industry.

Expanded scope-of-practice/health-and-wellness figure prominently in new strategy.